Benzinga · Oct 23, 2026
Abeona Therapeutics 13D Filing Shows James Russell Revocable Trust Raises Stake In Co To 6.1% As Of October 15, 2026
- SEC Filing
AB
NASDAQ · ABEO
Abeona Therapeutics Inc.
Healthcare · Biotechnology
$4.25
Up+$0.00 (+0.00%)
Updated Nov 3, 2026, 11:57 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 277.46M
- P/E ratio
- 3.37
- Dividend yield
- 0.00%
- 52-week range
- $4.00 – $7.65
- Volume
- 1.01M
- Avg. volume
- 1.15M
Price performance · ABEO
ABEO price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
ABEO closed at $4.25 after 20 trading sessions, down 15.17% for the selected period.
- Last close
- $4.25
- Period change
- -15.17%
- Period low
- $4.25
- Period high
- $5.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $4.43 | $4.4559 | $4.16 | $4.25 | 1.01M |
| Oct 30, 2026 | $4.50 | $4.53 | $4.305 | $4.35 | 783.43K |
| Oct 29, 2026 | $4.54 | $4.73 | $4.4701 | $4.56 | 874.33K |
| Oct 28, 2026 | $4.46 | $4.58 | $4.44 | $4.55 | 618.15K |
| Oct 27, 2026 | $4.33 | $4.495 | $4.30 | $4.45 | 663.68K |
| Oct 26, 2026 | $4.39 | $4.41 | $4.305 | $4.31 | 426.58K |
| Oct 23, 2026 | $4.42 | $4.435 | $4.29 | $4.40 | 797.29K |
| Oct 22, 2026 | $4.46 | $4.61 | $4.38 | $4.47 | 717.81K |
| Oct 21, 2026 | $4.62 | $4.67 | $4.50 | $4.51 | 643.56K |
| Oct 20, 2026 | $4.43 | $4.645 | $4.40 | $4.60 | 1.39M |
| Oct 19, 2026 | $4.47 | $4.49 | $4.32 | $4.41 | 986.05K |
| Oct 16, 2026 | $4.66 | $4.66 | $4.39 | $4.43 | 819.51K |
| Oct 15, 2026 | $4.39 | $4.785 | $4.35 | $4.65 | 1.38M |
| Oct 14, 2026 | $4.48 | $4.51 | $4.28 | $4.36 | 1.77M |
| Oct 13, 2026 | $4.88 | $4.88 | $4.505 | $4.52 | 1.98M |
| Oct 12, 2026 | $4.93 | $4.945 | $4.855 | $4.90 | 758.41K |
| Oct 9, 2026 | $4.94 | $5.04 | $4.885 | $4.94 | 1.28M |
| Oct 8, 2026 | $5.04 | $5.05 | $4.94 | $4.96 | 1.63M |
| Oct 7, 2026 | $4.95 | $5.10 | $4.93 | $5.08 | 738.34K |
| Oct 6, 2026 | $5.16 | $5.16 | $4.89 | $5.01 | 1.43M |
Latest ABEO news
The latest Smart Investors Daily articles mentioning ABEO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ABEO research
Overview
Company profile and research snapshot.
Company profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 17, 2026 | Roth Capital | Buy | — |
| Aug 14, 2026 | Oppenheimer | Outperform | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On September 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to,
Yahoo · Sep 22, 2026
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s senior vice president
Yahoo · Sep 22, 2026
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
